VK2735: trials, results, and current status.
Also searched as Viking VK2735 · oral VK2735 · GLP-1/GIP dual agonist
VK2735 is Viking Therapeutics' investigational peptide dual agonist of the GLP-1 and GIP receptors. The same active molecule is being developed as a once-weekly subcutaneous injection and a once-daily tablet. The injectable VANQUISH Phase 3 trials are fully enrolled, while the oral formulation has 13-week Phase 2 results and a sponsor-stated Phase 3 start target for late 2026. None of these records establishes approval, a commercial dose, or the identity of an online product.
Is VK2735 in Phase 3 or available now?
The once-weekly injectable formulation is in Phase 3. VANQUISH-1 and VANQUISH-2 are fully enrolled 78-week trials in adults without and with type 2 diabetes, respectively, but they have no posted Phase 3 outcomes as of this evidence check. Viking has stated that it expects to begin oral Phase 3 development in the fourth quarter of 2026. VK2735 is not FDA approved and has no legitimate approved retail product, label, commercial dose, pharmacy price, or routine prescribing channel. Online listings should not be treated as sponsor-authenticated clinical material.
Compare VK2735 with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about VK2735 today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
Mean change for the 15 mg weekly group versus 1.7% with placebo in the completed VENTURE trial.
Mean change for the 120 mg daily group versus 1.3% with placebo; treatment discontinuation rose with dose.
VANQUISH-1 studies obesity without type 2 diabetes and VANQUISH-2 studies a population with type 2 diabetes.
An end-of-Phase 2 meeting and active registration trials are development milestones, not marketing authorization.
Know which molecule the result belongs to.
- Sponsor
- Viking Therapeutics
- Mechanism
- GIP and GLP-1 receptor dual agonist
- Route being studied
- Once-weekly subcutaneous injection and once-daily oral tablet
- Current stage
- Subcutaneous Phase 3 active; oral Phase 3 planned
- Featured trial anchors
- NCT06068946 · NCT06828055 · NCT07104500 · NCT07104383
- Evidence checked
- July 18, 2026
VK2735 weight-loss results, with the trial attached.
These observations came from separate trials or formulations. Each percentage remains attached to its own duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026VK2735 injection reported 14.7% mean reduction at 13 weeks under the peer-reviewed 13-week mean. The comparator recorded 1.7% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight and at least one complication
- Participants
- 176 Total randomized trial population
- Dose
- 15 mg
- Primary analysis
- Peer-reviewed 13-week mean
- Regulatory status
- Investigational; not FDA approved
VK2735 oral reported 12.2% mean reduction at 13 weeks under the sponsor-reported 13-week mean. The comparator recorded 1.3% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight and at least one complication
- Participants
- 280 Total randomized trial population
- Dose
- 120 mg
- Primary analysis
- Sponsor-reported 13-week mean
- Regulatory status
- Investigational; not FDA approved
VK2735 clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 5 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24No individual location is marked Recruiting in this snapshot, so the table shows listed study footprints instead. A listed location is not an open enrollment site.
VK2735 across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare VK2735 by country →Compare VK2735 by US state →Browse the global peptide country dataset →Is VK2735 approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
Weekly injectable VK2735 has peer-reviewed Phase 2 evidence
The completed 13-week VENTURE trial randomized 176 adults with obesity or overweight and at least one weight-related condition, without diabetes, to four weekly VK2735 doses or placebo. The peer-reviewed report found mean weight reductions from 9.1% at 2.5 mg to 14.7% at 15 mg, compared with 1.7% for placebo. Gastrointestinal events were the most common adverse events, and the study cannot establish long-term outcomes or superiority over another medicine.
The oral tablet is a separate evidence track
VENTURE-Oral randomized 280 adults to five once-daily VK2735 dose strategies or placebo for 13 weeks. Viking reported mean weight change up to 12.2% at 120 mg versus 1.3% with placebo. Overall treatment discontinuation was 28% across VK2735 groups versus 18% with placebo, and the highest-dose group had a 38% early treatment-discontinuation rate. The sponsor's planned Phase 3 start does not convert this Phase 2 result into an approved oral regimen.
The injectable VANQUISH program is underway without outcomes
VANQUISH-1 and VANQUISH-2 are 78-week randomized Phase 3 trials of weekly 7.5 mg, 12.5 mg, or 17.5 mg VK2735 against placebo. The first studies adults without type 2 diabetes and the second studies adults with type 2 diabetes. Both are fully enrolled, but ClinicalTrials.gov lists no posted Phase 3 results as of this review, so enrollment status cannot support an efficacy, safety, approval, launch, or price claim.
No Phase 3 efficacy result is available
Fully enrolled trials establish that the registration program is active, not that it has demonstrated 78-week efficacy, durability, tolerability, or benefit-risk outcomes. Future topline reports still need the exact population, dose, estimand, placebo response, discontinuation data, and full trial context.
No approved oral or injectable product exists
VK2735 has no FDA-approved indication, final dose, prescribing information, retail price, pharmacy channel, insurance policy, or commercial presentation. The oral and injectable formulations remain investigational, and a listing that uses the VK2735 name does not become Viking clinical material by association.
Cross-trial speed and strength rankings remain invalid
A 13-week mean percentage cannot establish that VK2735 works faster or better than retatrutide, enicepatide, tirzepatide, semaglutide, or another program. Trial duration, population, dose escalation, route, analysis set, placebo response, discontinuations, adherence, rescue treatment, and missing-data handling all affect the reported number.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
What is VK2735 and how does it work?
VK2735 is a wholly owned investigational peptide from Viking Therapeutics designed to activate both the GLP-1 and GIP receptors. Viking is studying the same active molecule in two formulations: a once-weekly subcutaneous injection and a once-daily oral tablet. The injectable formulation has moved into the VANQUISH Phase 3 program, while the oral formulation has completed a 13-week Phase 2 dose-finding study. The mechanism and formulation strategy do not establish an approved indication, consumer dosing instructions, or the identity of any product offered online.
How much weight loss did VK2735 produce in its trials?
In the peer-reviewed 13-week injectable VENTURE trial, mean weight reduction ranged from 9.1% at 2.5 mg to 14.7% at 15 mg, compared with 1.7% for placebo. In the separate 13-week oral Phase 2 trial, Viking reported mean reduction up to 12.2% at 120 mg versus 1.3% with placebo. These results used different formulations, doses, and trial records. They are short-duration group averages, not predictions for an individual and not a fair direct comparison with a longer retatrutide, enicepatide, tirzepatide, or semaglutide trial.
Is VK2735 in Phase 3 or available now?
The once-weekly injectable formulation is in Phase 3. VANQUISH-1 and VANQUISH-2 are fully enrolled 78-week trials in adults without and with type 2 diabetes, respectively, but they have no posted Phase 3 outcomes as of this evidence check. Viking has stated that it expects to begin oral Phase 3 development in the fourth quarter of 2026. VK2735 is not FDA approved and has no legitimate approved retail product, label, commercial dose, pharmacy price, or routine prescribing channel. Online listings should not be treated as sponsor-authenticated clinical material.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →